PTC THERAPEUTICS INC (PTCT)
US69366J2006 - Common Stock
Taking everything into account, PTCT scores 2 out of 10 in our fundamental rating. PTCT was compared to 577 industry peers in the Biotechnology industry. PTCT has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, PTCT is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
PTCT had negative earnings in the past year.
In the past year PTCT has reported a negative cash flow from operations.
PTCT had negative earnings in each of the past 5 years.
In the past 5 years PTCT always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of PTCT (-32.37%) is better than 67.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.37% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-30.95%
ROA(5y)-25.64%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 92.88%, PTCT belongs to the top of the industry, outperforming 94.43% of the companies in the same industry.
PTCT's Gross Margin has been stable in the last couple of years.
PTCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.88% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-0.47%
2. Health
2.1 Basic Checks
PTCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
PTCT has more shares outstanding than it did 1 year ago.
PTCT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PTCT has a worse debt to assets ratio.
2.2 Solvency
PTCT has an Altman-Z score of -1.42. This is a bad value and indicates that PTCT is not financially healthy and even has some risk of bankruptcy.
PTCT has a Altman-Z score of -1.42. This is comparable to the rest of the industry: PTCT outperforms 52.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.42 |
ROIC/WACCN/A
WACC9.12%
2.3 Liquidity
PTCT has a Current Ratio of 2.03. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
PTCT has a worse Current ratio (2.03) than 76.31% of its industry peers.
A Quick Ratio of 1.98 indicates that PTCT should not have too much problems paying its short term obligations.
PTCT has a Quick ratio of 1.98. This is in the lower half of the industry: PTCT underperforms 74.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.03 | ||
| Quick Ratio | 1.98 |
3. Growth
3.1 Past
PTCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.13%, which is quite impressive.
The Revenue has grown by 20.40% in the past year. This is a very strong growth!
The Revenue has been growing by 28.79% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.17%
Revenue 1Y (TTM)20.4%
Revenue growth 3Y35.04%
Revenue growth 5Y28.79%
Sales Q2Q%-4.66%
3.2 Future
Based on estimates for the next years, PTCT will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.55% on average per year.
Based on estimates for the next years, PTCT will show a small growth in Revenue. The Revenue will grow by 6.40% on average per year.
EPS Next Y21.79%
EPS Next 2Y24.69%
EPS Next 3Y22.09%
EPS Next 5Y18.55%
Revenue Next Year-21.42%
Revenue Next 2Y-7.65%
Revenue Next 3Y-1.7%
Revenue Next 5Y6.4%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PTCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PTCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PTCT is valued cheaply inside the industry as 94.95% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 35.08 |
4.3 Compensation for Growth
PTCT's earnings are expected to grow with 22.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.69%
EPS Next 3Y22.09%
5. Dividend
5.1 Amount
PTCT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PTC THERAPEUTICS INC
NASDAQ:PTCT (7/26/2024, 7:00:01 PM)
After market: 34.09 0 (0%)34.09
+0.52 (+1.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.61B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.37% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.88% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.03 | ||
| Quick Ratio | 1.98 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)21.13%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y21.79%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)20.4%
Revenue growth 3Y35.04%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y